Research programme: long-acting neuropsychiatric therapeutics - Teva
Alternative Names: NP 201; NP 202; NP-202-Teva; NP201-Teva; Risperidone implant - Teva; Risperidone long-acting - Teva; Ropinirole implant - Teva; Ropinirole long-acting - TevaLatest Information Update: 04 Nov 2017
At a glance
- Originator NuPathe
- Developer Teva Pharmaceutical Industries
- Class Amines; Indoles; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bipolar disorders; Parkinson's disease; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bipolar-disorders in USA (Intradermal, Implant)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Intradermal, Implant)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA (Intradermal, Implant)